Xconomy National

Archives

by in

Entry	Author	Date	Location
Vertex Vows to Fight On With Alios Drugs in High-Stakes Hepatitis C Race	Luke Timmerman	01/24/12	Boston
Frazier Healthcare Aims for First Biotech VC Fund After Financial Crisis	Luke Timmerman	01/19/12	Seattle
Millennium: Takeda Acquires San Diego’s Intellikine for $190M Upfront	Luke Timmerman	12/20/11	Boston
Bruce Montgomery’s New Startup, Cardeas Pharma, Raises $5M	Luke Timmerman	12/20/11	Seattle
Vertex Names Jeff Leiden as New CEO, Staring Down Tough Competition	Luke Timmerman	12/15/11	Boston
The Hepatitis C Market: Biotech’s Version of the Daytona 500	Luke Timmerman	12/12/11	National
Theraclone Names Cliff Stocks, Vet of Icos & Calistoga, as New CEO	Luke Timmerman	12/06/11	Seattle
It Takes a Village to Raise a Biotech Startup: Highlights from the Tweetchat	Luke Timmerman	12/06/11	National
Join Us for a Tweetchat Monday on Biotech Startups	Luke Timmerman	12/02/11	National
Theraclone Nabs Industry Award, Scopes Out Extra $10M Financing	Luke Timmerman	09/06/11	Seattle
Dramatic Changes in Hepatitis C Treatment Expected to Continue	Steve Worland	09/06/11	San Diego
Scientists Spot New Antibodies Against HIV, Opening Up Potential Path to AIDS Vaccine	Luke Timmerman	08/17/11	National
Adventrx Shares Plummet, Pfizer Adds UC San Diego to its Network, New RNAi Center Opens, & More San Diego Life Sciences News	Bruce V. Bigelow	08/11/11	San Diego
Gilead HIV Drug Gets FDA OK	Luke Timmerman	08/10/11	San Francisco
Gilead Buys Genentech Biologics Plant	Bruce V. Bigelow	08/08/11	San Diego
Bristol-Myers Acquires Amira Pharmaceuticals for $325 Million, Scoops Up Lung Drug	Luke Timmerman	07/21/11	San Diego
Stop the M&A Obsession: Biotech Needs More Companies to Stay Independent	Luke Timmerman	07/18/11	National
Gilead Expands Low-Cost HIV Drug Program	Luke Timmerman	07/12/11	San Francisco
Why Twitter Matters Now in Biotech, and Why Executives Can’t Ignore it Anymore	Luke Timmerman	06/13/11	National
The Quest For Biotech Independence: Maybe It Isn’t So Quixotic After All	Luke Timmerman	06/06/11	National
AVI Biopharma CEO Chris Garabedian Seeks to Avoid Quick Flip, Build Enduring Drug Company	Luke Timmerman	06/02/11	Seattle
How to Make Money in Biotech With No Hope of Going Public, Slim Odds of Getting Acquired	Luke Timmerman	05/23/11	National
iPierian, Stem Cell Startup With Big Science & Big Bucks, Axes Group of Top Executives	Luke Timmerman	05/13/11	San Francisco
Pharma-Academic Alliances: What the Numbers Don’t Tell You	Stewart Lyman	05/10/11	Seattle
Gilead Cuts Deal With MicroDose	Luke Timmerman	04/20/11	San Francisco
Gilead Drug Fails AIDS Prevention Trial	Luke Timmerman	04/18/11	San Francisco
Gilead Antes Up for Cancer, Genentech Eye Drug Passes Big Trial, Bigger Isn’t Better, & More Bay Area Life Sciences News	Luke Timmerman	04/01/11	San Francisco
Editor’s Picks: Xconomy Seattle’s Top Stories of the First Quarter	Luke Timmerman	03/31/11	Seattle
Gilead Inks $100M Deal With Yale	Luke Timmerman	03/31/11	San Francisco
Doxo, Kashless, Physiosonic led WA’s Equity Financing Deals in February	Curt Woodward	03/21/11	Seattle
Page 1 of 4	next page »